Celltrion, Inc.
Biopharmaceutical firm developing biosimilars for autoimmune diseases and oncology.
068270 | KO
Overview
Corporate Details
- ISIN(s):
- KR7068270008
- LEI:
- Country:
- South Korea
- Address:
- 인천광역시 연수구 아카데미로 23, 인천광역시
- Website:
- https://www.celltrion.com/
- Sector:
- Manufacturing
Description
Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-11-12 00:00 |
투자판단관련주요경영사항(코로나19 바이러스(SARS-CoV-2) 감염환자 치료제(CT-P59) 유럽 CHMP(유럽의약품청 산하 약물사용자문위원…
|
Korean | 8.8 KB | ||
| 2021-11-10 00:00 |
영업(잠정)실적(공정공시)
|
Korean | 13.5 KB | ||
| 2021-11-10 00:00 |
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 15.2 KB | ||
| 2021-11-05 00:00 |
투자판단관련주요경영사항(도네페질 패취 식품의약품안전처 국내 품목 허가 획득)
|
Korean | 7.1 KB | ||
| 2021-11-03 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.4 KB | ||
| 2021-11-02 00:00 |
단일판매ㆍ공급계약체결
|
Korean | 7.4 KB | ||
| 2021-11-02 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.4 KB | ||
| 2021-11-02 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.4 KB | ||
| 2021-10-28 00:00 |
단일판매ㆍ공급계약체결
|
Korean | 7.5 KB | ||
| 2021-10-22 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 505.4 KB | ||
| 2021-10-15 00:00 |
투자판단관련주요경영사항(CT-P17(휴미라 바이오시밀러) 국내 품목허가 획득)
|
Korean | 10.9 KB | ||
| 2021-10-12 00:00 |
투자판단관련주요경영사항(CT-P16(아바스틴 바이오시밀러) 유럽 품목허가 신청)
|
Korean | 8.9 KB | ||
| 2021-10-05 00:00 |
투자판단관련주요경영사항(코로나19 바이러스(SARS-CoV-2) 감염환자 치료제(CT-P59) 유럽 정식 품목허가 신청)
|
Korean | 9.0 KB | ||
| 2021-10-01 00:00 |
투자판단관련주요경영사항(CT-P16(아바스틴 바이오시밀러) 미국 품목허가 신청)
|
Korean | 9.0 KB | ||
| 2021-10-01 00:00 |
[기재정정]투자판단관련주요경영사항(CT-P16(아바스틴 바이오시밀러) 미국 품목허가 신청)
|
Korean | 13.0 KB |
Automate Your Workflow. Get a real-time feed of all Celltrion, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Celltrion, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celltrion, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
